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Japanese encephalitis virus (JEV), a member of the genus Flavivirus in the family 
Flaviviridae is recognized as the leading cause of childhood viral encephalitis in Asia 
with approximately 50,000 cases and 10,000 to 15,000 deaths reported annually. 
Approximately 50% of the survivors display long-term neurological impairments that 
manifest as motor paralysis, speech and movement disorders, mental deficiency and 
abnormal emotional behavior. JE is endemic in many parts of Asia, including India, 
Nepal, Srilanka, Burma, China, Indonesia, Japan, Korea, Malaysia, Thailand, and 
Vietnam. Children one to fifteen years of age are predominantly affected in endemic 
areas while adult infections occur in areas where the disease is newly introduced. With no 
specific antiviral drugs available for JEV at present, vaccination is the only effective 
approach to prevent JE. A highly purified, formalin inactivated mouse brain derived 
commercial JE vaccine has been the most widely used and until recently, has been the 
only JE vaccine licensed in the international market. Although the efficacy of this vaccine 
is 91%, it has several limitations including very high manufacturing cost and high risk of 
exposure to extremely neurovirulent virus during manufacturing, in addition to 
stimulating systemic and allergic reactions in the vaccinees, attributed to mouse brain 
derived components in this preparation. Most importantly, for effective immunization the 
inactivated vaccine requires multiple doses because of its failure to maintain long-term 
memory. All these factors increase the cost of the vaccine, making it impractical to 
implement a common vaccination program in developing countries like India. Although 
an effective live attenuated SA 14-14-2 JE vaccine has been in use in China since 1988, 
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this vaccine is being introduced into other affected Asian countries including Nepal, 
South Korea and India only recently.  
 For protection against JEV, both neutralizing antibodies and virus specific T cells, 
including cytotoxic T lymphocytes (CTLs) have been considered important. The fact that 
majority of JEV-exposed individuals clear the viral infection without displaying the 
disease symptoms and that adults in JE-endemic areas rarely come down with disease 
suggest that repeated exposure to the virus in JE-endemic areas results in the 
development of protective immune responses. Identification of the JEV proteins targeted 
by these protective immune parameters will provide valuable information for the 
development of an improved JE vaccine. JEV is an enveloped virus with single strand, 
positive sense RNA genome, which encodes a single polyprotein that is co- and post-
translationally cleaved to produce three structural proteins- capsid (C), membrane (M)/ 
precursor membrane (prM), Envelope (E) and seven non-structural (NS) proteins - NS1, 
NS2a, NS2b, NS3, NS4a, NS4b, NS5. 
 We investigated the immune responses prevalent in convalescent JE patients and 
JEV exposed healthy individuals from Karnataka and Andhra Pradesh states of India. Our 
previous studies in individuals residing in JEV-endemic regions revealed T cell 
immunodominance of non structural proteins NS3 and NS1 during natural JEV infections 
in humans where as the structural protein E, which is a good target for neutralizing 
antibody response and the major component of the commercially available formalin 
inactivated vaccine is a poor inducer of T cells.  
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Role of JEV NS1 in protective immunity and in immunopathology. Flavivirus NS1 
exists as intracellular, cell surface associated, and extracellular non-virion forms. NS1 is 
also known to induce humoral immune response. Several studies in different flaviviruses 
have indicated a role for NS1-specific immune responses in protection against 
flaviviruses. Passive immunization studies in mice using monoclonal antibodies (MAbs) 
to Yellow fever virus (YFV), West Nile virus (WNV), and dengue virus (DENV) NS1 
showed that these antibodies are protective. Passive protection mediated by MAb to YFV 
NS1 correlated with in vitro complement mediated cytolysis of YFV infected cells. 
Similarly, many studies also showed that active immunization with purified NS1 protein, 
plasmid DNA or recombinant vaccinia virus expressing NS1 provides protection against 
lethal viral challenge. Paradoxically, studies also pointed to the contribution of NS1 in 
pathology and immune modulation. Antibodies directed to DENV NS1 were shown to 
cross react with platelets and extracellular matrix proteins as well as endothelial cells and 
cause inflammation and apoptosis. Immunization with DENV NS1 led to immune 
mediated liver injury in mice (Lin, C-F. et al., 2008. Lab Invest 88: 1079-1089). 
Recently, binding of soluble DENV NS1 to uninfected cells and tissues have been 
demonstrated and was implicated in the vascular leakage syndrome in severe DENV 
infections (Avirutnan, P. et al., 2007. PLoS Pathog 3: e183). Moreover, serum NS1 levels 
in DENV and WNV infected patients directly correlated with disease severity. Ability of 
WNV NS1 to bind to human complement regulatory protein factor H suggested a role of 
NS1 in immune modulation (Chung, K.M. et al., 2006. Proc Natl Acad Sci USA 103: 
19111-19116). Although literature is available on the contribution of immune responses 
to JEV NS1 towards protection in animal models, its role in human JEV infections and its 
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contribution to immunopathology or immune modulation in humans or animal models is 
not reported. We screened serum samples from 72 convalescent JE patients for the 
presence of anti-NS1 antibodies by ELISA and radioimmunoprecipitation and found NS1 
reactivity in 45 samples. First we wanted to address the question whether these antibodies 
to NS1 present in the serum of JEV infected human volunteers are capable of inducing 
complement mediated cytolysis of cells expressing NS1 on the surface. Since these 
human serum samples also contain antibodies to E and since JEV infected cells express 
both E and NS1 on the surface, we used a recombinant vaccinia virus to express JEV 
NS1 alone on the surface of target cells without any other JEV proteins. We generated 
recombinant vaccinia virus expressing JEV NS1 with its signal sequence (vNS1ss) and 
observed that the recombinant NS1 expressed by vaccinia virus is identical to authentic 
JEV NS1 in forming DTT stable dimers, expression on the surface of infected cells and 
secretion into the culture medium. Our results using BHK-21 cells or human derived SW-
13 cells expressing JEV NS1 on the surface showed significant cytolysis by anti-NS1 
antibody containing human serum in the presence of rabbit complement (with BHK-21 
cells) or human complement (with SW-13 cells). Additionally, we demonstrated twenty 
two fold reduction in the infectious virus produced at 48h in SW-13 cells in the presence 
of human complement and NS1 antiserum compared to control serum, suggesting that 
complement mediated cytolytic activity of anti-NS1 antibody helps the host in controlling 
the virus propagation. Interestingly, antibodies to JEV NS1 did not bring about cross 
cytolysis of West Nile virus (WNV) or dengue virus (DENV) infected cells despite cross 
recognition of their NS1 proteins. The role of JEV NS1 in immunopathology and immune 
modulation was next addressed. We used culture supernatant of JEV and vNS1ss infected 
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cells enriched for NS1 by ammonium sulphate fractionation for this purpose. Our results 
showed that JEV NS1, unlike DENV NS1 was not capable of binding to the surface of 
Vero, HepG2 and BHK-21 cells. Moreover, JEV NS1 failed to bind to complement 
regulatory protein factor H, a property which was demonstrated for WNV NS1 and was 
implicated in immune modulation by decreasing complement recognition of infected 
cells. In vivo experiments in the mouse model showed that the pre-existing circulating 
antibodies to JEV NS1 do not enhance severity of subsequent DENV or WNV infection. 
In fact, these mice were protected from lethal WNV challenge. Taken together these 
results suggest that JEV NS1 contributes to protective immune response without causing 
immunopathology or immune modulation. This is further substantiated by the 
observation of direct correlation of presence of anti-NS1 antibodies in the JE 
convalescent patients’ serum with better prognosis. We concluded from these findings 
that inclusion of NS1 in a vaccine should therefore enhance vaccine efficacy (Krishna, 
V.D. et al., 2009. J Virol 83: 4766-4777).  
 
Comparison of immune responses to JEV structural proteins Capsid and Envelope 
in human volunteers vaccinated with inactivated JE vaccine and naturally exposed 
to live JEV. Formalin inactivated JE vaccine contains only structural proteins of JEV and 
the non structural proteins are absent in this preparation. As mentioned earlier, 
inactivated JE vaccine is a poor inducer of long term immunity. We hypothesized that the 
absence of dominant T cell antigens NS3 and NS1 in the inactivated virus preparation 
could be one of the reasons for its inability to induce long term memory immune 
response since T cell help is required for stimulating long lasting immunity. We first 
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enquired whether differences in CMI responses to JEV structural proteins might be 
observed when provided as inactivated virus preparation without competing non 
structural proteins compared to that elicited upon live virus infection. We therefore 
measured CMI responses elicited by two of the three structural proteins C and E in 
human volunteers vaccinated with commercially available inactivated JE vaccine (n = 13) 
and in healthy, live JEV exposed individuals recruited from JE-endemic regions (n = 23). 
We found that the magnitude of lymphoproliferation in response to E was higher in live 
JEV exposed individuals compared to vaccinees while the level of IFN-γ produced in 
response to both C and E were similarly low in the two groups of volunteers. Both CD4+ 
and CD8+ T cells produced IFN-γ in live JEV exposed individuals where as IFN-γ was 
predominantly produced by CD4+ cells in killed JE vaccine immunized individuals. 
Taken together, these results suggest that structural proteins E and C are inherently poor 
inducers of T cells even in killed vaccine preparation, where there is no competition from 
immunodominant non structural proteins. In conclusion, inclusion of nonstructural 
proteins NS1 and NS3 along with neutralizing antibody inducing E should improve 
memory and consequent efficacy of the JE vaccine. 
      
Construction and testing in the Mouse Model of experimental recombinant poxvirus 
vaccines Expressing prM, E, NS1, and NS3 of JEV. Guided by the information on 
immune responses to JEV in the JE endemic human cohort and volunteers vaccinated 
with killed JE vaccine, we designed experimental vaccines as recombinant vaccinia 
viruses expressing NS1, NS3, prM, and E proteins of JEV (vNS1NS3prME) or NS1, 
NS3, prM, and C-terminally truncated E (vNS1NS3prMΔE), since this form of E was 
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reported to induce greater neutralizing antibody response and higher levels of protective 
immunity in mice compared to the full length E protein (Jan, L.R. et al., 1993. Am J Trop 
Med Hyg 48: 412-423). We also constructed recombinant vaccinia virus expressing only 
non structural proteins NS1 and NS3 (vNS1NS3) in addition to NS1 alone (vNS1ss). 
However, multiple attempts to express prM along with E or ΔE in recombinant vaccinia 
virus were not successful. We studied the immune responses elicited by these 
experimental vaccines in mice after immunization. Our data showed that a recombinant 
vaccinia virus expressing prM, ΔE, NS1, and NS3 of JEV (vNS1NS3prMΔE) is superior 
to formalin inactivated JE vaccine (JEvac) in eliciting long lived neutralizing antibodies. 
In addition, immunization with recombinant vaccinia viruses elicited NS1-specific 
antibodies with the ability to induce complement mediated lysis.  
We next analyzed the antigen specific proliferative response and IFN-γ 
production in response to purified E, NS1, and NS3 in the inguinal lymph node cells and 
splenocytes of immunized mice. As expected JEvac immunized mice responded only to E 
and not to nonstructural proteins tested. Moreover, both magnitude of lympho 
proliferation and level of IFN-γ production in response to E were significantly lower in 
JEvac immunized mice compared to vNS1NS3prMΔE immunized mice. Flowcytometry 
analysis of IFN-γ producing cells showed that lymphocytes from JEvac immunised mice 
predominantly recruited CD4+ over CD8+ T cells when stimulated in vitro with purified E 
whereas vNS1NS3prMΔE recruited both CD4+ and CD8+ T cells to produce IFN-γ 
similar to that observed in lymphocytes from live JEV immunized mice. Furthermore, we 
demonstrated the ability of JEV specific CTLs to recognize WNV infected target cells 
only from live JEV or recombinant vaccinia virus immunized mice but not from JEvac 
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immunized mice, suggesting that these cross reactive CTLs are specific to NS1 or NS3. 
Finally, to evaluate the protective immunity in recombinant vaccinia virus immunized 
mice we challenged these mice with 125 LD50 of JEV six weeks after the final boost. 
vNS1NS3prMΔE provided the maximum protection with 85.71% survival, statistically 
similar to mice immunized with JEvac that provided 62.5% protection. However, 
challenge studies performed six months after the final booster dose revealed significantly 
lower protection in JEvac immunized mice (37.5% survival) compared to 
vNS1NS3prMΔE immunized mice (87.5% survival). Importantly, when challenged 1 
year after administering the final booster dose none of the JEvac immunized mice 
survived after lethal JEV challenge (0/4) whereas vNS1NS3prMΔE provided 83.33% 
protection (5/6). Thus, inclusion of non structural proteins together with the live nature of 
the vNS1NS3prMΔE makes this vaccine superior to inactivated JE vaccine in eliciting 
long lived neutralizing antibodies as well as NS1 and NS3-specific CTLs along with 
NS1-specific antibodies with the ability to induce complement mediated lysis, resulting 
in long lasting and enhanced protection from lethal JEV infection in mice.  
Our results thus identified both B and T cell antigens whose inclusion in a live-
vectored vaccine would provide long lasting immunity with far superior efficacy over the 
inactivated JE vaccine.               
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